Cognition Therapeutics Inc (OQ:CGTX)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: Suite 261, 2403 Sidney Street
PITTSBURGH PA 15203
Tel: N/A
Website: https://cogrx.com
IR: See website
<
Key People
Lisa R. Ricciardi
President, Chief Executive Officer, Director
John Doyle
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
Anthony Caggiano
Chief Medical Officer, Head of R&D
Business Overview
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It is focused on developing a pipeline of small molecule product candidates that targets the sigma-2 receptor (S2R) complex, a key regulator of the cellular damage response for diseases, such as Alzheimer's disease (AD), dry age-related macular degeneration (dry AMD), geographic atrophy, and other conditions. The Company's lead product candidate, CT1812, is an orally delivered, small molecule modulator designed to penetrate the blood-brain barriers to the S2R complex, and through its modulation, S2R restores the normal function of synapses, as well as critical cellular processes, such as autophagy, cholesterol biosynthesis, vesicle trafficking, progesterone signaling lipid membrane-bound protein trafficking, and others.
Financial Overview
For the nine months ended 30 September 2023, Cognition Therapeutics Inc revenues was not reported. Net loss increased 9% to $17.6M. Higher net loss reflects Research & Development Expense - Balanci increase of 7% to $25.1M (expense), Stock-based Compensation in SGA increase of 23% to $2.8M (expense), Grant income decrease of 1% to $18M (income). Basic Earnings per Share excluding Extraordinary Items increased from -$0.71 to -$0.59.
Employees: 22 as of Mar 1, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $38.01M as of Dec 31, 2023
Annual revenue (TTM): $0.00M as of Dec 31, 2023
EBITDA (TTM): -$44.74M as of Dec 31, 2023
Net annual income (TTM): -$22.83M as of Dec 31, 2023
Free cash flow (TTM): -$20.87M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 39,000,152 as of Mar 11, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.